CommScope Holding is a provider of infrastructure solutions for communication networks. The company's solutions and services for wired and wireless networks enable high-bandwidth data, video and voice applications. The company's operating segments are: CommScope Connectivity Solutions (CCS) and CommScope Mobility Solutions (CMS). The CCS segment is engaged in providing fiber optic and copper connectivity solutions for use in data centers and business enterprise, telecommunications, cable television and residential broadband networks. The CMS segment is engaged in providing infrastructure for wireless networks.

CVD Equipment designs, develops and manufactures a range of chemical vapor deposition, gas control and other equipment and process solutions used to develop and manufacture materials and coatings for research and industrial applications. The company operates through three segments: CVD/First Nano, which supplies chemical vapor deposition systems; SDC, which designs and manufactures ultra-high purity gas and chemical delivery control systems; and CVD Materials, which has several elements and product groups including the Tantaline corrosion resistant surface treatment, the MesoScribe direct write, the Electronic Materials for electronics and Carbon Composite products.

Heron Therapeutics is a commercial-stage biotechnology company. The company is developing patient-focused solutions that apply its science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. The company develops SUSTOL for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide combination chemotherapy regimens. The company's second commercial product, CINVANTI, is indicated for the prevention of acute and delayed nausea and vomiting associated with of highly emetogenic cancer chemotherapy and nausea and vomiting associated with MEC.

Natural Resource Partners owns, manages and leases a portfolio of mineral properties, including interests in coal, soda ash from trona and other natural resources. The company has two segments: coal royalty and other, which consists primarily of coal royalty properties and coal related transportation and processing assets; and soda ash, which, via Ciner Resources LP, the company's operating partner, mines trona, processes it into soda ash, and distributes the soda ash both domestically and internationally into the glass and chemicals industries. The company's operations are conducted through its NRP (Operating) LLC susbsidiary, and its operating assets are owned by its subsidiaries.

NGM Biopharmaceuticals is a biopharmaceutical company. The company is focused on the following programs: Aldafermin, which is for the treatment of non-alcoholic steatohepatitis (NASH); NGM313 (MK-3655), which is for the treatment of NASH and type 2 diabetes; NGM120, which is designed to block the effects of elevated growth differentiation factor 15 levels on cancer anorexia/cachexia syndrome, and, possibly, tumors; NGM217, which is designed to restore pancreatic islet function and increase insulin production in patients with diabetes; NGM621, which is designed to decrease levels of this protein implicated in the dry form of AMD; and NGM395, which is for the treatment of metabolic syndrome.